Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 242 participants.
Also called NCT04454788
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 242 participants
- Sponsor
- Registry
-
NCT04454788
-
- Other papers using this trial's data
- Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia
- Registry status
- Terminated
Technical summary
Registry record NCT04454788. Randomized; no masking; primary purpose treatment. Start 2020-08-01 (actual); primary completion 2024-07-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion
- Acronym
- ETERNAL-LVO
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Tenecteplase
- Intervention (Drug)
- Standard Care (which may include intravenous Alteplase)
- Lead sponsor
- University of Melbourne
- Collaborator
- Professor Mark Parsons
Record details
- Record id
cardio:ct-nct04454788- Content hash
301df9b8c26614689fd81e97a2090d1a5cf8f6c5d6e7e6299504140ed07c05fa